These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38054392)

  • 41. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy.
    Pang B; Zhou H; Kuang H
    Peptides; 2018 Feb; 100():123-126. PubMed ID: 28807775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.
    Brunetti VC; St-Jean A; Dell'Aniello S; Fisher A; Yu OHY; Bugden SC; Daigle JM; Hu N; Alessi-Severini S; Shah BR; Ronksley PE; Lix LM; Ernst P; Filion KB;
    BMC Endocr Disord; 2022 Sep; 22(1):241. PubMed ID: 36175881
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis.
    Lee YM; Lee SH; Kim TH; Park EJ; Park YA; Jang JS
    Cardiol J; 2022; 29(3):499-508. PubMed ID: 33140391
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of sodium glucose co-transporter inhibitors in heart failure prevention.
    Garla V; Subauste A; Butler J; Lien LF
    J Diabetes Complications; 2021 Mar; 35(3):107811. PubMed ID: 33280983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
    Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comment on: Acute abdomen as a side-effect of sodium-glucose co-transporter 2 inhibitors in diabetic patients.
    Patoulias D; Patoulias I
    Br J Surg; 2022 Mar; 109(4):e67. PubMed ID: 35020821
    [No Abstract]   [Full Text] [Related]  

  • 48. Diabetes: From Research to Clinical Practice.
    Islam MS
    Adv Exp Med Biol; 2021; 1307():1-5. PubMed ID: 32583142
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
    Khan MS; Fonarow GC; McGuire DK; Hernandez AF; Vaduganathan M; Rosenstock J; Handelsman Y; Verma S; Anker SD; McMurray JJV; Kosiborod MN; Butler J
    Circulation; 2020 Sep; 142(12):1205-1218. PubMed ID: 32955939
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Author response to: Acute abdomen as a side-effect of sodium-glucose co-transporter 2 inhibitors in diabetic patients.
    Kietaibl AT; Fasching P; Glaser K; Petter-Puchner AH
    Br J Surg; 2022 Mar; 109(4):e68. PubMed ID: 35020810
    [No Abstract]   [Full Text] [Related]  

  • 51. SGLT2 Inhibitors and GLP-1 Agonists: A Beacon of Hope for Stroke Prevention in Diabetes.
    Jeon JH
    Diabetes Metab J; 2024 Mar; 48(2):213-214. PubMed ID: 38556704
    [No Abstract]   [Full Text] [Related]  

  • 52. Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists.
    Volpe M; Gallo G
    Cardiovasc Res; 2021 Jul; 117(9):1992-1994. PubMed ID: 33231613
    [No Abstract]   [Full Text] [Related]  

  • 53. Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.
    Crea F
    Eur Heart J; 2020 Sep; 41(36):3379-3383. PubMed ID: 33216881
    [No Abstract]   [Full Text] [Related]  

  • 54. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile.
    Muzurović E; Mikhailidis DP
    Expert Opin Pharmacother; 2020 Dec; 21(17):2125-2135. PubMed ID: 32697112
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer M
    Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
    [No Abstract]   [Full Text] [Related]  

  • 57. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.
    Gómez-Huelgas R; Sanz-Cánovas J; Cobos-Palacios L; López-Sampalo A; Pérez-Belmonte LM
    Eur J Intern Med; 2022 Feb; 96():26-33. PubMed ID: 34799233
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?
    Patoulias D; Papadopoulos C; Doumas M
    Diabetes Metab Syndr; 2020; 14(4):347. PubMed ID: 32305776
    [No Abstract]   [Full Text] [Related]  

  • 59. Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review.
    Ntentakis DP; Correa VSMC; Ntentaki AM; Delavogia E; Narimatsu T; Efstathiou NE; Vavvas DG
    Graefes Arch Clin Exp Ophthalmol; 2024 Mar; 262(3):717-752. PubMed ID: 37728754
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease.
    Rhee JJ; Han J; Montez-Rath ME; Chertow GM
    Diabetes Obes Metab; 2024 Apr; 26(4):1273-1281. PubMed ID: 38186297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.